Loading
Somatostatin receptor 2 is a hormone receptor densely present on neuroendocrine tumours, and was the first theranostic target to reach routine care. This dossier gathers the 9 products (5 approved), 22 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
G-protein-coupled receptor; also expressed in meningioma, small-cell lung cancer, and some breast cancers.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Neuroendocrine tumours | 80-90% | SSTR PET positivity (well-differentiated) | Lower in grade 3 | Wikipedia |
| Small-cell lung cancer | 30-50% | IHC/imaging | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Phase 3 | Phase 2 |
|---|---|---|---|
| Radiopharmaceutical 4 | |||
| Small molecule 2 | - | - | |
| Imaging agent 1 | - | - | |
| Multireceptor somatostatin analogue 1 | - | - | |
| Peptide somatostatin analogue 1 | - | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
COMPETE NCT03049189 | 3 | Positive | Progressive grade 1-2 SSTR-positive GEP-NETs: 177Lu-edotreotide vs everolimus | PFS 23.9 vs 14.1 months, HR 0.67. | |
| 3 | Active | A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET | - | ||
SPINET NCT02683941 | 3 | Mixed | Unresectable or metastatic well-differentiated typical or atypical lung neuroendocrine tumours: lanreotide autogel against placebo | Closed early for slow recruitment; the underpowered comparison favoured lanreotide over placebo for progression-free survival. | |
| 3 | Completed | Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone | - | ||
NETTER-1 NCT01578239 | 3 | Positive | Inoperable, progressive midgut neuroendocrine tumours: 177Lu-Dotatate plus octreotide versus high-dose octreotide LAR | PFS at 20 months 65.2% vs 10.8% (HR 0.21); ORR 18% vs 3%. | |
| 3 | Completed | A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly | - | ||
| 3 | Completed | A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly | - | ||
CLARINET NCT00353496 | 3 | Positive | Non-functioning enteropancreatic NETs, grade 1-2: lanreotide 120 mg vs placebo | PFS HR 0.47. | |
| 3 | Completed | A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease | - | ||
PROMID NCT00171873 | 3 | Positive | Treatment-naive metastatic midgut NETs: octreotide LAR vs placebo | TTP 14.3 vs 6.0 months, HR 0.34. | |
68Ga-DOTA-TATE PET/CT Imaging in NETs NCT04847505 | 3 | - | Pragmatic Study on the Use of 68Ga-DOTA-TATE PET|CT Imaging as a Standard of Care to Influence Clinical Management | - | |
| 3 | Active | A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET | - | ||
ACTION-1 NCT05477576 | 3 | Recruiting | SSTR-positive GEP-NETs progressing after 177Lu somatostatin-analogue therapy: 225Ac-DOTATATE (RYZ101) vs investigator's choice | - | |
| 3 | Recruiting | A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors | - | ||
| 3 | Recruiting | Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. | - | ||
| 3 | Recruiting | A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula | - | ||
| 3 | Active | A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin | - | ||
ALPHAMEDIX-02 NCT05153772 | 2 | Positive | Unresectable or metastatic SSTR-positive GEP-NETs, PRRT-naive and PRRT-exposed cohorts: 212Pb-DOTAMTATE single arm | ORR 54.3% (PRRT-naive); all primary endpoints met. | |
| 2 | Active | A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL) | - | ||
Study of Dotatate Imaging in Breast Cancer NCT05880394 | 2 | - | Somatostatin Receptor Imaging Study of Estrogen Receptor Positive (ER+) Metastatic Breast Cancer | - | |
| 1/2 | Active | A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase | - | ||
| 1/2 | Active | Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1). | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Somatostatin receptor 2" OR ABSTRACT:"Somatostatin receptor 2" OR TITLE:"SSTR2" OR ABSTRACT:"SSTR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Somatostatin receptor 2, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/sstr2.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/sstr2.json. Licence CC BY-NC 4.0.